Renal Cell Carcinoma News
Women with type 2 diabetes have a 1.5-fold higher risk of renal cell carcinoma compared with non-diabetic women.
The phase 3 METEOR study previously demonstrated that cabozantinib significantly improved survival outcomes among patients with relapsed renal cell carcinoma.
Approval was based on results from the randomized phase 3 CheckMate-214 study.
The standard schedule is associated with AEs including grade 3 to 4 fatigue, HFS, and diarrhea.
Previous studies showed that combination therapy with nivolumab and ipilimumab has promising efficacy for various cancers, including RCC, compared with either agent alone.
Researchers enrolled 6 and 49 patients into dose-finding and dose expansion stages, respectively.
Previous studies found that an elevated pH environment leads to nearly a 40% reduction in pazopanib exposure.
Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.
Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.
Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.
Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.
The phase 3 METEOR trial demonstrated that cabozantinib prolonged PFS, OS, and ORR compared with everolimus, but the impact on QoL was not fully established.
The drug was, however, associated with a greater number of grade 3 to 4 adverse events.
The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.
A cumulative-use analysis suggests that NSAIDs, ACEis, and SSRIs improve disease-specific outcomes among patients with kidney cancer, and further that NSAIDs improve overall survival.
Thirty to 40% of patients with RCC relapse a median of 2 years after nephrectomy. The majority of relapses occur within 5 years.
A review of data from the CABOSUN and CheckMate-214 trials to determine the use of targeted therapy in metastatic renal cell carcinoma.
For CheckMate-025, 803 patients with RCC previously treated with anti-angiogenic therapy were assigned to receive IV nivolumab every 2 weeks or oral everolimus once daily.
Previous studies have associated miR-181a dysregulation with various cancers, such as acute lymphoblastic leukemia as well as colon, breast, and pancreatic cancers, but its role in ccRCC is unknown.
Patients in all subgroups who received adjuvant sunitinib had a DFS benefit compared with placebo, including patients who were at a higher risk of recurrence.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC
- Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma
- Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia
- Pediatric CML: Life-Long Considerations With TKI Therapy
- Reducing Dose Intensity May Be Associated with Shortened PFS in Waldenstrom Macroglobulinemia
- Nelarabine May Improve Disease-Free Survival in Pediatric and Young Adult T-cell ALL
- Lung Cancer Screening Rates Inadequate in United States Despite USPSTF Recommendations
- Can Oncolytic Viruses Improve Immunotherapies?
- Cognitive Behavioral Therapy Compared With Acupuncture for Insomnia in Cancer Survivors
- CYCORE System May Improve Radiotherapy-Associated Symptoms in Head and Neck Cancer